{"id": "article-143337_0", "title": "Small Interfering RNA (siRNA) Therapy -- Continuing Education Activity", "content": "This activity focuses on small interfering RNA (siRNA) therapy, exemplified by FDA-approved agents such as patisiran, givosiran, lumasiran, inclisiran, nedosiran, and vutrisiran. These therapies are pivotal in managing rare metabolic ailments, including hereditary transthyretin amyloidosis (hATTR), acute hepatic porphyria (AHP), primary hyperoxaluria type 1 (PH1), and lowering low-density lipoprotein cholesterol (LDL-C) in subjects with heterozygous familial hypercholesterolemia (HeFH) or clinical atherosclerotic cardiovascular disease (ASCVD). The activity will\u00a0discuss the mechanism of action of siRNA, its adverse event profile, and other key factors essential for interprofessional team members involved in patient care. Furthermore, participants will gain insights into administration techniques, contraindications, clinical toxicology, and monitoring strategies necessary to safely and effectively utilize siRNA therapies in clinical practice.", "contents": "Small Interfering RNA (siRNA) Therapy -- Continuing Education Activity. This activity focuses on small interfering RNA (siRNA) therapy, exemplified by FDA-approved agents such as patisiran, givosiran, lumasiran, inclisiran, nedosiran, and vutrisiran. These therapies are pivotal in managing rare metabolic ailments, including hereditary transthyretin amyloidosis (hATTR), acute hepatic porphyria (AHP), primary hyperoxaluria type 1 (PH1), and lowering low-density lipoprotein cholesterol (LDL-C) in subjects with heterozygous familial hypercholesterolemia (HeFH) or clinical atherosclerotic cardiovascular disease (ASCVD). The activity will\u00a0discuss the mechanism of action of siRNA, its adverse event profile, and other key factors essential for interprofessional team members involved in patient care. Furthermore, participants will gain insights into administration techniques, contraindications, clinical toxicology, and monitoring strategies necessary to safely and effectively utilize siRNA therapies in clinical practice."}
{"id": "article-143337_1", "title": "Small Interfering RNA (siRNA) Therapy -- Continuing Education Activity", "content": "Understanding the intricate pharmacology of siRNA is crucial for healthcare professionals to deliver precise therapeutic interventions in various clinical scenarios. This activity equips participants with comprehensive knowledge encompassing the mechanism of action, potential adverse reactions, and contraindications, empowering them to integrate advanced therapeutic strategies into patient care. This comprehension ensures that professionals possess the requisite expertise to provide optimal and innovative patient care within the dynamic realm of medical science, thereby enhancing patient outcomes and contributing to the advancement of medical practice.", "contents": "Small Interfering RNA (siRNA) Therapy -- Continuing Education Activity. Understanding the intricate pharmacology of siRNA is crucial for healthcare professionals to deliver precise therapeutic interventions in various clinical scenarios. This activity equips participants with comprehensive knowledge encompassing the mechanism of action, potential adverse reactions, and contraindications, empowering them to integrate advanced therapeutic strategies into patient care. This comprehension ensures that professionals possess the requisite expertise to provide optimal and innovative patient care within the dynamic realm of medical science, thereby enhancing patient outcomes and contributing to the advancement of medical practice."}
{"id": "article-143337_2", "title": "Small Interfering RNA (siRNA) Therapy -- Continuing Education Activity", "content": "Objectives: Evaluate\u00a0the mechanism of action of small interfering RNA (siRNA)-based therapies. Identify the appropriate monitoring for patients receiving small interfering RNA (siRNA)-based therapies. Assess the potential adverse effects of small interfering RNA (siRNA)-based therapies. Implement\u00a0interprofessional team strategies for improving care coordination and communication to advance small interfering RNA (siRNA)-based therapies in treating patients with\u00a0various conditions. Access free multiple choice questions on this topic.", "contents": "Small Interfering RNA (siRNA) Therapy -- Continuing Education Activity. Objectives: Evaluate\u00a0the mechanism of action of small interfering RNA (siRNA)-based therapies. Identify the appropriate monitoring for patients receiving small interfering RNA (siRNA)-based therapies. Assess the potential adverse effects of small interfering RNA (siRNA)-based therapies. Implement\u00a0interprofessional team strategies for improving care coordination and communication to advance small interfering RNA (siRNA)-based therapies in treating patients with\u00a0various conditions. Access free multiple choice questions on this topic."}
{"id": "article-143337_3", "title": "Small Interfering RNA (siRNA) Therapy -- Indications -- FDA-Approved Indications", "content": "Small interfering ribonucleic acid (siRNA)-based therapies have been\u00a0developed for the past 20 years. The first siRNA agent, patisiran, received US Food Drug Administration (FDA) approval in 2018. To date, the FDA has approved\u00a06 siRNA agents: patisiran, givosiran, lumasiran, inclisiran, nedosiran and vutisiran.", "contents": "Small Interfering RNA (siRNA) Therapy -- Indications -- FDA-Approved Indications. Small interfering ribonucleic acid (siRNA)-based therapies have been\u00a0developed for the past 20 years. The first siRNA agent, patisiran, received US Food Drug Administration (FDA) approval in 2018. To date, the FDA has approved\u00a06 siRNA agents: patisiran, givosiran, lumasiran, inclisiran, nedosiran and vutisiran."}
{"id": "article-143337_4", "title": "Small Interfering RNA (siRNA) Therapy -- Indications -- FDA-Approved Indications", "content": "Patisiran was the first siRNA agent to receive approval from the FDA on August 10, 2018, and is indicated in adult subjects with polyneuropathy due to hereditary transthyretin amyloidosis (hATTR). [1] A year later, givosiran was the second\u00a0siRNA agent to receive approval by the FDA.\u00a0Patisiran\u00a0was indicated in adult subjects with acute hepatic porphyria (AHP). [2] Lumasiran\u00a0was the third\u00a0siRNA agent to receive approval by the FDA on November 23, 2020 and was to be used in pediatric and adult subjects with primary hyperoxaluria type 1 (PH1) and reduced urinary oxalate levels. [3] The siRNA agent to receive FDA approval on December\u00a021, 2021 was inclisiran. The agent is indicated in adult subjects with heterozygous familial hypercholesterolemia (HeFH)/clinical atherosclerotic cardiovascular disease (ASCVD) and lowers the levels of\u00a0LDL-C. [4]", "contents": "Small Interfering RNA (siRNA) Therapy -- Indications -- FDA-Approved Indications. Patisiran was the first siRNA agent to receive approval from the FDA on August 10, 2018, and is indicated in adult subjects with polyneuropathy due to hereditary transthyretin amyloidosis (hATTR). [1] A year later, givosiran was the second\u00a0siRNA agent to receive approval by the FDA.\u00a0Patisiran\u00a0was indicated in adult subjects with acute hepatic porphyria (AHP). [2] Lumasiran\u00a0was the third\u00a0siRNA agent to receive approval by the FDA on November 23, 2020 and was to be used in pediatric and adult subjects with primary hyperoxaluria type 1 (PH1) and reduced urinary oxalate levels. [3] The siRNA agent to receive FDA approval on December\u00a021, 2021 was inclisiran. The agent is indicated in adult subjects with heterozygous familial hypercholesterolemia (HeFH)/clinical atherosclerotic cardiovascular disease (ASCVD) and lowers the levels of\u00a0LDL-C. [4]"}
{"id": "article-143337_5", "title": "Small Interfering RNA (siRNA) Therapy -- Indications -- FDA-Approved Indications", "content": "According to the American Heart Association/American College of Cardiology, in patients with clinical cardiovascular disease on maximally tolerated statin therapy and having LDL-C levels \u226570 mg/dL and when ezetimibe and PCSK9 monoclonal antibody are considered insufficient or not tolerated, it may be helpful to add bempedoic acid/inclisiran (in place of PCSK9 monoclonal antibody) to reduce LDL-C levels additionally. [5]", "contents": "Small Interfering RNA (siRNA) Therapy -- Indications -- FDA-Approved Indications. According to the American Heart Association/American College of Cardiology, in patients with clinical cardiovascular disease on maximally tolerated statin therapy and having LDL-C levels \u226570 mg/dL and when ezetimibe and PCSK9 monoclonal antibody are considered insufficient or not tolerated, it may be helpful to add bempedoic acid/inclisiran (in place of PCSK9 monoclonal antibody) to reduce LDL-C levels additionally. [5]"}
{"id": "article-143337_6", "title": "Small Interfering RNA (siRNA) Therapy -- Indications -- FDA-Approved Indications", "content": "In accordance with the 2022 AHA/ACC/HFSA guidelines, available data indicates that patisiran is associated with a slowed progression of amyloidosis-related polyneuropathy in individuals with hereditary transthyretin-mediated amyloidosis with cardiomyopathy (ATTRv-CM). [6]", "contents": "Small Interfering RNA (siRNA) Therapy -- Indications -- FDA-Approved Indications. In accordance with the 2022 AHA/ACC/HFSA guidelines, available data indicates that patisiran is associated with a slowed progression of amyloidosis-related polyneuropathy in individuals with hereditary transthyretin-mediated amyloidosis with cardiomyopathy (ATTRv-CM). [6]"}
{"id": "article-143337_7", "title": "Small Interfering RNA (siRNA) Therapy -- Indications -- FDA-Approved Indications", "content": "Nedosiran exerts its effects by acting on the hepatic enzyme lactate dehydrogenase, whereas lumasiran acts on the hepatic enzyme glyoxylate oxidase.\u00a0Nedosiran and vutrisiran have recently received FDA approval. Vutisiran is now FDA-approved\u00a0transthyretin-directed small interfering RNA indicated for polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults. [7] Nedosiran injection has received FDA approval for the treatment of primary hyperoxaluria type 1 in both children (9 and older) and adults. [8]", "contents": "Small Interfering RNA (siRNA) Therapy -- Indications -- FDA-Approved Indications. Nedosiran exerts its effects by acting on the hepatic enzyme lactate dehydrogenase, whereas lumasiran acts on the hepatic enzyme glyoxylate oxidase.\u00a0Nedosiran and vutrisiran have recently received FDA approval. Vutisiran is now FDA-approved\u00a0transthyretin-directed small interfering RNA indicated for polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults. [7] Nedosiran injection has received FDA approval for the treatment of primary hyperoxaluria type 1 in both children (9 and older) and adults. [8]"}
{"id": "article-143337_8", "title": "Small Interfering RNA (siRNA) Therapy -- Indications -- FDA-Approved Indications", "content": "Other siRNA-based therapies are currently being evaluated in clinical trials (fitusiran, teprasiran, cosdosiran, and tivanisiran). Other ailments\u00a0currently being assessed for management with siRNA-based therapies include hemophilia A and hemophilia B (fitusiran), prophylactic therapy for acute kidney injury (AKI) in patients undergoing transplantation or following cardiovascular surgery (teprasiran), nonarteritic anterior ischemic optic neuropathy, and primary angle glaucoma (cosdosiran), ocular pain and dry eye disease (tivanisiran). [9] Indications can be summarized below.", "contents": "Small Interfering RNA (siRNA) Therapy -- Indications -- FDA-Approved Indications. Other siRNA-based therapies are currently being evaluated in clinical trials (fitusiran, teprasiran, cosdosiran, and tivanisiran). Other ailments\u00a0currently being assessed for management with siRNA-based therapies include hemophilia A and hemophilia B (fitusiran), prophylactic therapy for acute kidney injury (AKI) in patients undergoing transplantation or following cardiovascular surgery (teprasiran), nonarteritic anterior ischemic optic neuropathy, and primary angle glaucoma (cosdosiran), ocular pain and dry eye disease (tivanisiran). [9] Indications can be summarized below."}
{"id": "article-143337_9", "title": "Small Interfering RNA (siRNA) Therapy -- Mechanism of Action", "content": "The siRNAs are identified as small double-stranded RNAs that exert their effects by dividing into single strands and binding to their distinct target messenger RNA (mRNA) sequences. This action catalyzes a string of activities that yield the target mRNA to\u00a0degrade, further halting translation and inducing gene suppression by the short RNA strands.\u00a0This enzyme is also known\u00a0as RNA interference (RNAi). [9] [10]", "contents": "Small Interfering RNA (siRNA) Therapy -- Mechanism of Action. The siRNAs are identified as small double-stranded RNAs that exert their effects by dividing into single strands and binding to their distinct target messenger RNA (mRNA) sequences. This action catalyzes a string of activities that yield the target mRNA to\u00a0degrade, further halting translation and inducing gene suppression by the short RNA strands.\u00a0This enzyme is also known\u00a0as RNA interference (RNAi). [9] [10]"}
{"id": "article-143337_10", "title": "Small Interfering RNA (siRNA) Therapy -- Mechanism of Action", "content": "The siRNA agents initiate their RNAi action in the cytoplasm with the help of an enzyme, endoribonuclease dicer, also known as helicase, with an RNase motif.\u00a0Helicase cleaves the double-stranded RNA and yields a siRNA.", "contents": "Small Interfering RNA (siRNA) Therapy -- Mechanism of Action. The siRNA agents initiate their RNAi action in the cytoplasm with the help of an enzyme, endoribonuclease dicer, also known as helicase, with an RNase motif.\u00a0Helicase cleaves the double-stranded RNA and yields a siRNA."}
{"id": "article-143337_11", "title": "Small Interfering RNA (siRNA) Therapy -- Mechanism of Action", "content": "The short double-strand RNA fragments integrate with a cluster of essential proteins known as the RNA-induced silencing complex (RISC) and are then split into\u00a02 single RNA strands recognized as sense and antisense. The single antisense strand further targets its mRNA arrangement while the sense strand is dismissed from the complex.\u00a0The essential enzymes in the RISC complex, such as the Ago-2 endonucleases, cleave their target mRNA sequence once affixed. [9] [10] [11]", "contents": "Small Interfering RNA (siRNA) Therapy -- Mechanism of Action. The short double-strand RNA fragments integrate with a cluster of essential proteins known as the RNA-induced silencing complex (RISC) and are then split into\u00a02 single RNA strands recognized as sense and antisense. The single antisense strand further targets its mRNA arrangement while the sense strand is dismissed from the complex.\u00a0The essential enzymes in the RISC complex, such as the Ago-2 endonucleases, cleave their target mRNA sequence once affixed. [9] [10] [11]"}
{"id": "article-143337_12", "title": "Small Interfering RNA (siRNA) Therapy -- Mechanism of Action", "content": "Patisiran: Patisiran exerts its mechanism of action through RNAi, resulting in cleavage and breakdown of all types (mutant and wild-type) of transthyretin (TTR) mRNA. The agent is a\u00a0double-stranded siRNA\u00a0formulated as a lipid nanoparticle (LNP) taken up by hepatocytes once bound to apolipoprotein E (APOE)\u00a0receptors. The TTR mRNA's RNAi decreases the TTR protein's circulation production and deposition in tissues and organs. [12] [13]", "contents": "Small Interfering RNA (siRNA) Therapy -- Mechanism of Action. Patisiran: Patisiran exerts its mechanism of action through RNAi, resulting in cleavage and breakdown of all types (mutant and wild-type) of transthyretin (TTR) mRNA. The agent is a\u00a0double-stranded siRNA\u00a0formulated as a lipid nanoparticle (LNP) taken up by hepatocytes once bound to apolipoprotein E (APOE)\u00a0receptors. The TTR mRNA's RNAi decreases the TTR protein's circulation production and deposition in tissues and organs. [12] [13]"}
{"id": "article-143337_13", "title": "Small Interfering RNA (siRNA) Therapy -- Mechanism of Action", "content": "Givosiran: Givosiran exerts its mechanism of action through RNAi, resulting in the cleavage and breakdown of its target, aminolevulinate synthase 1 (ALAS1) mRNA, found in the liver. The agent is a double-stranded siRNA conjugated\u00a0with N -acetylgalactosamine (GalNAc) ligand for hepatocyte intake. Once taken up by hepatocytes and degrading its target mRNA, it decreases aminolevulinic acid (ALA) and porphobilinogen (PBG) levels in the blood, further limiting AHP disease characteristics. [14] [2]", "contents": "Small Interfering RNA (siRNA) Therapy -- Mechanism of Action. Givosiran: Givosiran exerts its mechanism of action through RNAi, resulting in the cleavage and breakdown of its target, aminolevulinate synthase 1 (ALAS1) mRNA, found in the liver. The agent is a double-stranded siRNA conjugated\u00a0with N -acetylgalactosamine (GalNAc) ligand for hepatocyte intake. Once taken up by hepatocytes and degrading its target mRNA, it decreases aminolevulinic acid (ALA) and porphobilinogen (PBG) levels in the blood, further limiting AHP disease characteristics. [14] [2]"}
{"id": "article-143337_14", "title": "Small Interfering RNA (siRNA) Therapy -- Mechanism of Action", "content": "Lumasiran: Lumasiran exerts its mechanism of action through RNAi in the liver, resulting in cleavage and breakdown of its target, hydroxy acid oxidase 1 (HAO1) mRNA. The agent is a double-stranded siRNA conjugated\u00a0with GalNAc\u00a0ligand\u00a0for effective hepatocyte uptake.\u00a0HAO1 produces glycolate oxidase (GO), an enzyme responsible for producing glyoxylate, a substrate for the further synthesis of oxalate. The inhibition of the GO enzyme results in decreased oxalate precursor levels, reducing the production of the enzyme alanine glyoxylate aminotransferase (AGT) that is mutated in PH1. [9] [15] [14]", "contents": "Small Interfering RNA (siRNA) Therapy -- Mechanism of Action. Lumasiran: Lumasiran exerts its mechanism of action through RNAi in the liver, resulting in cleavage and breakdown of its target, hydroxy acid oxidase 1 (HAO1) mRNA. The agent is a double-stranded siRNA conjugated\u00a0with GalNAc\u00a0ligand\u00a0for effective hepatocyte uptake.\u00a0HAO1 produces glycolate oxidase (GO), an enzyme responsible for producing glyoxylate, a substrate for the further synthesis of oxalate. The inhibition of the GO enzyme results in decreased oxalate precursor levels, reducing the production of the enzyme alanine glyoxylate aminotransferase (AGT) that is mutated in PH1. [9] [15] [14]"}
{"id": "article-143337_15", "title": "Small Interfering RNA (siRNA) Therapy -- Mechanism of Action", "content": "Inclisiran: Inclisiran exerts its mechanism of action through RNAi in the liver and orchestrates hepatic mRNA degradation of proprotein convertase subtilisin/kexin type-9 (PCSK9). The sense strand of the siRNA is bound with the GalNAc\u00a0ligand, allowing hepatocytes to uptake the siRNA agent and target PCSK9 efficiently. PCSK9 internalizes and breaks down the hepatic LDL receptors once attached. Inclisiran inhibits this action of PCSK9, further promoting the expression of LDL-C receptors on the cell's surface and facilitating receptor cycling. Once LDL-C is bound to its receptor, it is subject to degradation by lysosomal enzymes and recycled back to the cell's surface. This results in a raised uptake of LDL-C and reduces its levels in the blood. [16]", "contents": "Small Interfering RNA (siRNA) Therapy -- Mechanism of Action. Inclisiran: Inclisiran exerts its mechanism of action through RNAi in the liver and orchestrates hepatic mRNA degradation of proprotein convertase subtilisin/kexin type-9 (PCSK9). The sense strand of the siRNA is bound with the GalNAc\u00a0ligand, allowing hepatocytes to uptake the siRNA agent and target PCSK9 efficiently. PCSK9 internalizes and breaks down the hepatic LDL receptors once attached. Inclisiran inhibits this action of PCSK9, further promoting the expression of LDL-C receptors on the cell's surface and facilitating receptor cycling. Once LDL-C is bound to its receptor, it is subject to degradation by lysosomal enzymes and recycled back to the cell's surface. This results in a raised uptake of LDL-C and reduces its levels in the blood. [16]"}
{"id": "article-143337_16", "title": "Small Interfering RNA (siRNA) Therapy -- Mechanism of Action", "content": "Nedosiran: Nedosiran, a double-stranded small interfering RNA (siRNA) conjugated to GalNAc aminosugar residues, is administered subcutaneously. Upon administration, the GalNAc-conjugated sugars bind to asialoglycoprotein receptors (ASGPR), facilitating nedosiran delivery to hepatocytes. The siRNA action of nedosiran leads to the degradation of hepatic lactate dehydrogenase (LDH) by targeting LDHA messenger ribonucleic acid (mRNA) through RNA interference. This reduction in hepatic LDH levels diminishes oxalate production by the liver, subsequently\u00a0reducing the oxalate burden. [17]", "contents": "Small Interfering RNA (siRNA) Therapy -- Mechanism of Action. Nedosiran: Nedosiran, a double-stranded small interfering RNA (siRNA) conjugated to GalNAc aminosugar residues, is administered subcutaneously. Upon administration, the GalNAc-conjugated sugars bind to asialoglycoprotein receptors (ASGPR), facilitating nedosiran delivery to hepatocytes. The siRNA action of nedosiran leads to the degradation of hepatic lactate dehydrogenase (LDH) by targeting LDHA messenger ribonucleic acid (mRNA) through RNA interference. This reduction in hepatic LDH levels diminishes oxalate production by the liver, subsequently\u00a0reducing the oxalate burden. [17]"}
{"id": "article-143337_17", "title": "Small Interfering RNA (siRNA) Therapy -- Mechanism of Action", "content": "Vutrisiran: Vutrisiran, a double-stranded small interfering RNA (siRNA) with a GalNAc conjugate, induces the degradation of mutant and wild-type transthyretin (TTR) mRNA through RNA interference. This mechanism leads to a decrease in serum TTR protein levels and the deposition of TTR protein in tissues. [7]", "contents": "Small Interfering RNA (siRNA) Therapy -- Mechanism of Action. Vutrisiran: Vutrisiran, a double-stranded small interfering RNA (siRNA) with a GalNAc conjugate, induces the degradation of mutant and wild-type transthyretin (TTR) mRNA through RNA interference. This mechanism leads to a decrease in serum TTR protein levels and the deposition of TTR protein in tissues. [7]"}
{"id": "article-143337_18", "title": "Small Interfering RNA (siRNA) Therapy -- Administration -- Patisiran", "content": "Patisiran is available\u00a0and distributed as a single-dose vial of 10 mg/5 mL (2 mg/mL). A lipid complex injection should be filtered and diluted before administering. A healthcare professional should calculate and adjust the correct dosage according to the patient's body weight and\u00a0administer it as an intervenous infusion. Indication: polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults. 0.3 mg/kg once every\u00a03 weeks (weight <100 kg) 30 mg once every\u00a03 weeks (weight \u2265100 kg) Patisiran should be administered immediately if an\u00a0earlier dose was missed. Patients given\u00a0a dose within\u00a03 days from a missed dosage should\u00a0follow their original regime.", "contents": "Small Interfering RNA (siRNA) Therapy -- Administration -- Patisiran. Patisiran is available\u00a0and distributed as a single-dose vial of 10 mg/5 mL (2 mg/mL). A lipid complex injection should be filtered and diluted before administering. A healthcare professional should calculate and adjust the correct dosage according to the patient's body weight and\u00a0administer it as an intervenous infusion. Indication: polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults. 0.3 mg/kg once every\u00a03 weeks (weight <100 kg) 30 mg once every\u00a03 weeks (weight \u2265100 kg) Patisiran should be administered immediately if an\u00a0earlier dose was missed. Patients given\u00a0a dose within\u00a03 days from a missed dosage should\u00a0follow their original regime."}
{"id": "article-143337_19", "title": "Small Interfering RNA (siRNA) Therapy -- Administration -- Patisiran", "content": "Patients receiving\u00a0treatment with patisiran are advised to receive\u00a0premedication therapy 60 minutes before\u00a0administration of the IV infusion to decrease the occurrence of infusion-related reactions (IRRs). Premedication therapies consist of corticosteroids (IV), acetaminophen (oral), H1 blockers (IV), and H2 blockers (IV).", "contents": "Small Interfering RNA (siRNA) Therapy -- Administration -- Patisiran. Patients receiving\u00a0treatment with patisiran are advised to receive\u00a0premedication therapy 60 minutes before\u00a0administration of the IV infusion to decrease the occurrence of infusion-related reactions (IRRs). Premedication therapies consist of corticosteroids (IV), acetaminophen (oral), H1 blockers (IV), and H2 blockers (IV)."}
{"id": "article-143337_20", "title": "Small Interfering RNA (siRNA) Therapy -- Administration -- Givosiran", "content": "Givosiran is available and distributed as a single-dose vial of\u00a0189 mg/mL for subcutaneous injection. Indication: acute hepatic porphyria in adults. 2.5 mg/kg once monthly", "contents": "Small Interfering RNA (siRNA) Therapy -- Administration -- Givosiran. Givosiran is available and distributed as a single-dose vial of\u00a0189 mg/mL for subcutaneous injection. Indication: acute hepatic porphyria in adults. 2.5 mg/kg once monthly"}
{"id": "article-143337_21", "title": "Small Interfering RNA (siRNA) Therapy -- Administration -- Givosiran", "content": "Givosiran should be administered immediately if a prior dosage was missed and continued monthly afterward. Patients with critical elevations in liver transaminases should decrease their dosage to\u00a01.25 mg/kg every month. In subjects who do not show a recurring increase in\u00a0transaminases while receiving therapy at 1.25 mg/kg, the dosage can be increased to 2.5 mg/kg.", "contents": "Small Interfering RNA (siRNA) Therapy -- Administration -- Givosiran. Givosiran should be administered immediately if a prior dosage was missed and continued monthly afterward. Patients with critical elevations in liver transaminases should decrease their dosage to\u00a01.25 mg/kg every month. In subjects who do not show a recurring increase in\u00a0transaminases while receiving therapy at 1.25 mg/kg, the dosage can be increased to 2.5 mg/kg."}
{"id": "article-143337_22", "title": "Small Interfering RNA (siRNA) Therapy -- Administration -- Lumasiran", "content": "Lumasiran\u00a0is available and distributed as a single-dose vial\u00a0of\u00a094.5 mg/0.5 mL for subcutaneous injection.\u00a0Lumasiran is administered as\u00a0loading doses accompanied by\u00a0maintenance doses calculated and adjusted according to the patient's body weight. Indication: PH1 adult and pediatric subjects. Initial loading dose: 6 mg/kg administered\u00a0once a month for\u00a03 doses (weight <10 kg) Maintenance dose: 3 mg/kg administered once a month (weight\u00a0<10 kg) Initial loading dose: 6 mg/kg administered once a month\u00a0for\u00a03 doses (10 to 20 kg) Maintenance dose:\u00a06 mg/kg administered once every\u00a03 months quarterly\u00a0(10 to 20 kg) Initial loading dose: 3 mg/kg administered once a month for\u00a03 doses (\u226520 kg) Maintenance dose: 3 mg/kg administered once every\u00a03 months (\u226520 kg) Lumasiran should be administered immediately if a prior dosage was missed and continued monthly thereafter.", "contents": "Small Interfering RNA (siRNA) Therapy -- Administration -- Lumasiran. Lumasiran\u00a0is available and distributed as a single-dose vial\u00a0of\u00a094.5 mg/0.5 mL for subcutaneous injection.\u00a0Lumasiran is administered as\u00a0loading doses accompanied by\u00a0maintenance doses calculated and adjusted according to the patient's body weight. Indication: PH1 adult and pediatric subjects. Initial loading dose: 6 mg/kg administered\u00a0once a month for\u00a03 doses (weight <10 kg) Maintenance dose: 3 mg/kg administered once a month (weight\u00a0<10 kg) Initial loading dose: 6 mg/kg administered once a month\u00a0for\u00a03 doses (10 to 20 kg) Maintenance dose:\u00a06 mg/kg administered once every\u00a03 months quarterly\u00a0(10 to 20 kg) Initial loading dose: 3 mg/kg administered once a month for\u00a03 doses (\u226520 kg) Maintenance dose: 3 mg/kg administered once every\u00a03 months (\u226520 kg) Lumasiran should be administered immediately if a prior dosage was missed and continued monthly thereafter."}
{"id": "article-143337_23", "title": "Small Interfering RNA (siRNA) Therapy -- Administration -- Inclisiran", "content": "Inclisiran is available and distributed as a pre-filled single-dose vial of 284 mg/1.5 mL (189 mg/mL) for subcutaneous injection. Indication: reducing LDL-C in subjects with HeFH or ASCVD\u00a0adjunctive to diet and statin therapy tolerated at a maximum dose. 284 mg (initial dose) 284 mg (at\u00a03 months) 284 mg (every\u00a06 months after that)", "contents": "Small Interfering RNA (siRNA) Therapy -- Administration -- Inclisiran. Inclisiran is available and distributed as a pre-filled single-dose vial of 284 mg/1.5 mL (189 mg/mL) for subcutaneous injection. Indication: reducing LDL-C in subjects with HeFH or ASCVD\u00a0adjunctive to diet and statin therapy tolerated at a maximum dose. 284 mg (initial dose) 284 mg (at\u00a03 months) 284 mg (every\u00a06 months after that)"}
{"id": "article-143337_24", "title": "Small Interfering RNA (siRNA) Therapy -- Administration -- Inclisiran", "content": "Inclisiran should be administered immediately if a prior dosage was missed. Patients given\u00a0a dosage within\u00a03 months of a missed dosage are recommended to\u00a0follow their original regime. If a dose\u00a0has been missed for\u00a0more than\u00a03 months, therapy\u00a0should be initiated at\u00a03 months\u00a0following administration of the missed dosage and every\u00a06 months after that.", "contents": "Small Interfering RNA (siRNA) Therapy -- Administration -- Inclisiran. Inclisiran should be administered immediately if a prior dosage was missed. Patients given\u00a0a dosage within\u00a03 months of a missed dosage are recommended to\u00a0follow their original regime. If a dose\u00a0has been missed for\u00a0more than\u00a03 months, therapy\u00a0should be initiated at\u00a03 months\u00a0following administration of the missed dosage and every\u00a06 months after that."}
{"id": "article-143337_25", "title": "Small Interfering RNA (siRNA) Therapy -- Administration -- Nedosiran", "content": "Nedosiran is available in 128mg/0.8 mL as a single-dose pre-filled syringe and 160 mg/mL as a single-dose pre-filled syringe, both intended for subcutaneous injection. Indication: Lower urinary oxalate levels are reduced in individuals aged 9 and older with primary hyperoxaluria type 1 (PH1) and preserved kidney function (eGFR \u2265 30 mL/min/1.73 m2). Adults and Adolescents (age 12 and older) Greater than or equal to 50 kg: 160 mg once monthly (pre-filled syringe, 1 mL) Less than 50 kg: 128 mg once monthly (pre-filled syringe, 0.8 mL) Children (ages 9 to 11) Greater than or equal to 50 kg: 160 mg once monthly (pre-filled syringe, 1 mL) Less than 50 kg: 3.3 mg/kg once monthly, not to exceed 128 mg (round to nearest 0.1 mL)", "contents": "Small Interfering RNA (siRNA) Therapy -- Administration -- Nedosiran. Nedosiran is available in 128mg/0.8 mL as a single-dose pre-filled syringe and 160 mg/mL as a single-dose pre-filled syringe, both intended for subcutaneous injection. Indication: Lower urinary oxalate levels are reduced in individuals aged 9 and older with primary hyperoxaluria type 1 (PH1) and preserved kidney function (eGFR \u2265 30 mL/min/1.73 m2). Adults and Adolescents (age 12 and older) Greater than or equal to 50 kg: 160 mg once monthly (pre-filled syringe, 1 mL) Less than 50 kg: 128 mg once monthly (pre-filled syringe, 0.8 mL) Children (ages 9 to 11) Greater than or equal to 50 kg: 160 mg once monthly (pre-filled syringe, 1 mL) Less than 50 kg: 3.3 mg/kg once monthly, not to exceed 128 mg (round to nearest 0.1 mL)"}
{"id": "article-143337_26", "title": "Small Interfering RNA (siRNA) Therapy -- Administration -- Vutrisiran", "content": "Vutisiran is available as a single-dose pre-filled syringe containing 25 mg/0.5 mL for subcutaneous injection. Indication:\u00a0Polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults. Recommended Dosage:\u00a025 mg administered by subcutaneous injection once every 3 months.", "contents": "Small Interfering RNA (siRNA) Therapy -- Administration -- Vutrisiran. Vutisiran is available as a single-dose pre-filled syringe containing 25 mg/0.5 mL for subcutaneous injection. Indication:\u00a0Polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults. Recommended Dosage:\u00a025 mg administered by subcutaneous injection once every 3 months."}
{"id": "article-143337_27", "title": "Small Interfering RNA (siRNA) Therapy -- Administration -- Vutrisiran", "content": "It is recommended that the recommended amount of vitamin A be supplemented daily while taking vutrisiran. If any ocular symptoms that suggest a vitamin A deficiency occur, it is recommended to consult an ophthalmologist. [7]", "contents": "Small Interfering RNA (siRNA) Therapy -- Administration -- Vutrisiran. It is recommended that the recommended amount of vitamin A be supplemented daily while taking vutrisiran. If any ocular symptoms that suggest a vitamin A deficiency occur, it is recommended to consult an ophthalmologist. [7]"}
{"id": "article-143337_28", "title": "Small Interfering RNA (siRNA) Therapy -- Adverse Effects", "content": "Adverse events are listed by the agent below. [16]", "contents": "Small Interfering RNA (siRNA) Therapy -- Adverse Effects. Adverse events are listed by the agent below. [16]"}
{"id": "article-143337_29", "title": "Small Interfering RNA (siRNA) Therapy -- Adverse Effects -- Patisiran", "content": "Upper respiratory tract infections (URTI) (28%) Infusion-related reactions (19%) Dyspepsia\u00a0(8%) Dyspnea\u00a0(8%) Muscle spasms\u00a0(8%) Arthralgia\u00a0(7%) Erythema (7%) Bronchitis (7%) Vertigo\u00a0(5%)", "contents": "Small Interfering RNA (siRNA) Therapy -- Adverse Effects -- Patisiran. Upper respiratory tract infections (URTI) (28%) Infusion-related reactions (19%) Dyspepsia\u00a0(8%) Dyspnea\u00a0(8%) Muscle spasms\u00a0(8%) Arthralgia\u00a0(7%) Erythema (7%) Bronchitis (7%) Vertigo\u00a0(5%)"}
{"id": "article-143337_30", "title": "Small Interfering RNA (siRNA) Therapy -- Adverse Effects -- Givosiran", "content": "Nausea (27%) Injection site reactions (25%) Rash (17%) Serum creatinine increase (15%) Elevated liver transaminases (13%) Fatigue (10%)", "contents": "Small Interfering RNA (siRNA) Therapy -- Adverse Effects -- Givosiran. Nausea (27%) Injection site reactions (25%) Rash (17%) Serum creatinine increase (15%) Elevated liver transaminases (13%) Fatigue (10%)"}
{"id": "article-143337_31", "title": "Small Interfering RNA (siRNA) Therapy -- Adverse Effects -- Lumasiran", "content": "Injection site reactions (38%) Abdominal pain/discomfort (15%)", "contents": "Small Interfering RNA (siRNA) Therapy -- Adverse Effects -- Lumasiran. Injection site reactions (38%) Abdominal pain/discomfort (15%)"}
{"id": "article-143337_32", "title": "Small Interfering RNA (siRNA) Therapy -- Adverse Effects -- Inclisiran", "content": "Arthralgia (4%) Urinary tract infection (3.6%) Diarrhea (3.5%) Bronchitis (2.7%) Pain in extremity\u00a0(2.6%) Dyspnea (2.6%) Injection site reaction (1.8%)", "contents": "Small Interfering RNA (siRNA) Therapy -- Adverse Effects -- Inclisiran. Arthralgia (4%) Urinary tract infection (3.6%) Diarrhea (3.5%) Bronchitis (2.7%) Pain in extremity\u00a0(2.6%) Dyspnea (2.6%) Injection site reaction (1.8%)"}
{"id": "article-143337_33", "title": "Small Interfering RNA (siRNA) Therapy -- Adverse Effects -- Nedosiran", "content": "Injection site reactions (\u226520%) [18]", "contents": "Small Interfering RNA (siRNA) Therapy -- Adverse Effects -- Nedosiran. Injection site reactions (\u226520%) [18]"}
{"id": "article-143337_34", "title": "Small Interfering RNA (siRNA) Therapy -- Adverse Effects -- Vutrisiran", "content": "Pain in extremity (15%) Arthralgia (11%) Dyspnea (7%) Vitamin A deficiency (7%) [7] Injection site reactions (4%) Rare case report of atrioventricular block. [19]", "contents": "Small Interfering RNA (siRNA) Therapy -- Adverse Effects -- Vutrisiran. Pain in extremity (15%) Arthralgia (11%) Dyspnea (7%) Vitamin A deficiency (7%) [7] Injection site reactions (4%) Rare case report of atrioventricular block. [19]"}
{"id": "article-143337_35", "title": "Small Interfering RNA (siRNA) Therapy -- Contraindications", "content": "No labeled contraindications have been reported for patisiran, lumasiran, neodosiran, vutisiran and inclisiran. Hypersensitivity to givosiran is an absolute contraindication to therapy. [20] Anaphylaxis\u00a0has been\u00a0reported in\u00a0<1% of subjects during clinical trials with givosiran. [21]", "contents": "Small Interfering RNA (siRNA) Therapy -- Contraindications. No labeled contraindications have been reported for patisiran, lumasiran, neodosiran, vutisiran and inclisiran. Hypersensitivity to givosiran is an absolute contraindication to therapy. [20] Anaphylaxis\u00a0has been\u00a0reported in\u00a0<1% of subjects during clinical trials with givosiran. [21]"}
{"id": "article-143337_36", "title": "Small Interfering RNA (siRNA) Therapy -- Monitoring", "content": "Patients receiving therapy with patisiran should be monitored for infusion-related adverse responses such as hypersensitivity reactions and anaphylaxis. Treatment with patisiran should be delayed or interrupted, and appropriate management should be initiated as clinically required. Infusion should be resumed gradually once adverse manifestations are resolved. In the event of critical infusion-related adverse responses, therapy should not be continued.\u00a0Patients receiving treatment with patisiran should also have their vitamin A levels monitored routinely as therapy decreases its levels. Patients should be initiated on vitamin A supplementation that does not exceed the recommended daily dosage and monitored for clinical manifestations of vitamin A deficiency. [22]", "contents": "Small Interfering RNA (siRNA) Therapy -- Monitoring. Patients receiving therapy with patisiran should be monitored for infusion-related adverse responses such as hypersensitivity reactions and anaphylaxis. Treatment with patisiran should be delayed or interrupted, and appropriate management should be initiated as clinically required. Infusion should be resumed gradually once adverse manifestations are resolved. In the event of critical infusion-related adverse responses, therapy should not be continued.\u00a0Patients receiving treatment with patisiran should also have their vitamin A levels monitored routinely as therapy decreases its levels. Patients should be initiated on vitamin A supplementation that does not exceed the recommended daily dosage and monitored for clinical manifestations of vitamin A deficiency. [22]"}
{"id": "article-143337_37", "title": "Small Interfering RNA (siRNA) Therapy -- Monitoring", "content": "Liver function tests (LFTs) should be monitored at baseline and routinely after that in patients receiving treatment with givosiran, as an increase in alanine transaminase (ALT) was observed during clinical trials. Elevation in liver function is reported to occur around 3 to 5 months from the initiation of therapy. Recommendations are to measure LFTs monthly for the first\u00a06 months of givosiran. Treatment should be discontinued in patients with severe elevations in ALT. Baseline and routine monitoring of estimated glomerular filtration rate (eGFR) and serum creatinine levels is recommended along with LFTs when receiving givosiran. Alterations in eGFR and creatinine were reported during clinical trials.", "contents": "Small Interfering RNA (siRNA) Therapy -- Monitoring. Liver function tests (LFTs) should be monitored at baseline and routinely after that in patients receiving treatment with givosiran, as an increase in alanine transaminase (ALT) was observed during clinical trials. Elevation in liver function is reported to occur around 3 to 5 months from the initiation of therapy. Recommendations are to measure LFTs monthly for the first\u00a06 months of givosiran. Treatment should be discontinued in patients with severe elevations in ALT. Baseline and routine monitoring of estimated glomerular filtration rate (eGFR) and serum creatinine levels is recommended along with LFTs when receiving givosiran. Alterations in eGFR and creatinine were reported during clinical trials."}
{"id": "article-143337_38", "title": "Small Interfering RNA (siRNA) Therapy -- Monitoring", "content": "Patients receiving givosiran should also have their homocysteine levels measured at baseline and routinely afterward. Elevations in homocysteine levels in the blood were reported in 16% of subjects during clinical trials. Patients with evidence of homocysteine elevations should have their vitamin B9 and B12 levels assessed and consider initiating vitamin B6 supplementation.", "contents": "Small Interfering RNA (siRNA) Therapy -- Monitoring. Patients receiving givosiran should also have their homocysteine levels measured at baseline and routinely afterward. Elevations in homocysteine levels in the blood were reported in 16% of subjects during clinical trials. Patients with evidence of homocysteine elevations should have their vitamin B9 and B12 levels assessed and consider initiating vitamin B6 supplementation."}
{"id": "article-143337_39", "title": "Small Interfering RNA (siRNA) Therapy -- Monitoring", "content": "Immunogenicity with all siRNA agents is possible and may be a barrier to therapeutic delivery. An unwanted biological immunogenic response may identify siRNA as a viral RNA antigen, provoking undesirable adverse reactions. During clinical trials, anti-drug antibodies (ADA) developed in 3.6% of subjects receiving patisiran, 6% of subjects receiving lumasiran, 0.9% of subjects receiving givosiran, 1.8% of subjects before inclisiran dosing, and 4.9% of subjects at 18 months therapy. ADA did not influence effectiveness or safety in all siRNA agents, resulting in no clinically significant discrepancies in the pharmacokinetics and pharmacodynamics. [23]", "contents": "Small Interfering RNA (siRNA) Therapy -- Monitoring. Immunogenicity with all siRNA agents is possible and may be a barrier to therapeutic delivery. An unwanted biological immunogenic response may identify siRNA as a viral RNA antigen, provoking undesirable adverse reactions. During clinical trials, anti-drug antibodies (ADA) developed in 3.6% of subjects receiving patisiran, 6% of subjects receiving lumasiran, 0.9% of subjects receiving givosiran, 1.8% of subjects before inclisiran dosing, and 4.9% of subjects at 18 months therapy. ADA did not influence effectiveness or safety in all siRNA agents, resulting in no clinically significant discrepancies in the pharmacokinetics and pharmacodynamics. [23]"}
{"id": "article-143337_40", "title": "Small Interfering RNA (siRNA) Therapy -- Toxicity", "content": "During clinical trials with givosiran, hepatic and renal toxicity was reported. Fifteen percent of subjects receiving therapy reported ALT elevations\u00a03 times above the normal range. Fifteen percent of subjects reported elevated serum creatinine levels and reductions in eGFR, with a median elevation in creatinine of 0.07 mg/dL at\u00a03 months. The severity of laboratory alterations and clinical symptoms should determine whether to continue therapy.", "contents": "Small Interfering RNA (siRNA) Therapy -- Toxicity. During clinical trials with givosiran, hepatic and renal toxicity was reported. Fifteen percent of subjects receiving therapy reported ALT elevations\u00a03 times above the normal range. Fifteen percent of subjects reported elevated serum creatinine levels and reductions in eGFR, with a median elevation in creatinine of 0.07 mg/dL at\u00a03 months. The severity of laboratory alterations and clinical symptoms should determine whether to continue therapy."}
{"id": "article-143337_41", "title": "Small Interfering RNA (siRNA) Therapy -- Toxicity -- Pregnancy", "content": "Data on using patisiran and lumasiran therapy during pregnancy has not been reported. A reduction in vitamin A levels is recognized with patisiran use, a crucial component of normal embryo maturation and fetal development. An excess in vitamin A levels correlates with adverse effects on the fetus.", "contents": "Small Interfering RNA (siRNA) Therapy -- Toxicity -- Pregnancy. Data on using patisiran and lumasiran therapy during pregnancy has not been reported. A reduction in vitamin A levels is recognized with patisiran use, a crucial component of normal embryo maturation and fetal development. An excess in vitamin A levels correlates with adverse effects on the fetus."}
{"id": "article-143337_42", "title": "Small Interfering RNA (siRNA) Therapy -- Toxicity -- Pregnancy", "content": "Although givosiran was not studied in humans during pregnancy, animal reproduction analyses demonstrated unfavorable developmental effects during organogenesis. Givosiran during pregnancy should be assessed, weighing the advantages and dangers to the mother and probable impacts on the developing fetus.\u00a0Inclisiran therapy is recommended to be discontinued during pregnancy. This agent's mechanism of action has been reported to decrease cholesterol, and biologically active substances may harm the developing fetus. [24]", "contents": "Small Interfering RNA (siRNA) Therapy -- Toxicity -- Pregnancy. Although givosiran was not studied in humans during pregnancy, animal reproduction analyses demonstrated unfavorable developmental effects during organogenesis. Givosiran during pregnancy should be assessed, weighing the advantages and dangers to the mother and probable impacts on the developing fetus.\u00a0Inclisiran therapy is recommended to be discontinued during pregnancy. This agent's mechanism of action has been reported to decrease cholesterol, and biologically active substances may harm the developing fetus. [24]"}
{"id": "article-143337_43", "title": "Small Interfering RNA (siRNA) Therapy -- Enhancing Healthcare Team Outcomes", "content": "Small interfering ribonucleic acid (siRNA) based therapies have\u00a0recently\u00a0been approved as therapeutics exerting their effects by RNAi on their target mRNA in the liver. To date,\u00a06 agents (patisiran, givosiran, lumasiran, inclisiran, nedosiran, and vutisiran) are FDA-approved for managing adult patients with hATTR, AHP, reducing LDL-C in subjects with HeFH or ASCVD, and PH1 in adults and pediatric patients. Caring for patients with rare metabolic ailments demands care coordination from a team of healthcare professionals. The healthcare team should include a primary care physician (PCP), a hematologist, a nephrologist, a cardiologist, a physician assistant, a nurse practitioner, a clinical geneticist, nurses, and a pharmacist.", "contents": "Small Interfering RNA (siRNA) Therapy -- Enhancing Healthcare Team Outcomes. Small interfering ribonucleic acid (siRNA) based therapies have\u00a0recently\u00a0been approved as therapeutics exerting their effects by RNAi on their target mRNA in the liver. To date,\u00a06 agents (patisiran, givosiran, lumasiran, inclisiran, nedosiran, and vutisiran) are FDA-approved for managing adult patients with hATTR, AHP, reducing LDL-C in subjects with HeFH or ASCVD, and PH1 in adults and pediatric patients. Caring for patients with rare metabolic ailments demands care coordination from a team of healthcare professionals. The healthcare team should include a primary care physician (PCP), a hematologist, a nephrologist, a cardiologist, a physician assistant, a nurse practitioner, a clinical geneticist, nurses, and a pharmacist."}
{"id": "article-143337_44", "title": "Small Interfering RNA (siRNA) Therapy -- Enhancing Healthcare Team Outcomes", "content": "The healthcare team should conduct a thorough clinical examination to assess if the management of siRNA-based therapies suits the patient. Before prompting treatment, the interprofessional team should determine the patient's laboratory values, such as renal and liver function (givosiran), lipid levels (inclisiran), and vitamin A levels (patisiran, vutisiran) at baseline and\u00a0periodically.\u00a0The PCP should regularly communicate with the other specialists caring for such patients.", "contents": "Small Interfering RNA (siRNA) Therapy -- Enhancing Healthcare Team Outcomes. The healthcare team should conduct a thorough clinical examination to assess if the management of siRNA-based therapies suits the patient. Before prompting treatment, the interprofessional team should determine the patient's laboratory values, such as renal and liver function (givosiran), lipid levels (inclisiran), and vitamin A levels (patisiran, vutisiran) at baseline and\u00a0periodically.\u00a0The PCP should regularly communicate with the other specialists caring for such patients."}
{"id": "article-143337_45", "title": "Small Interfering RNA (siRNA) Therapy -- Enhancing Healthcare Team Outcomes", "content": "The healthcare team should administer the abovementioned premedications (corticosteroid, acetaminophen, H1 blocker, and\u00a0H2 blocker) at least 60 minutes before the infusion to prevent an infusion-related reaction. The prescribing and administering clinician should be prepared and equipped for immediate adverse effects such as infusion-related hypersensitivity reactions. The healthcare team should monitor for headaches, back pain, abdominal pain, shortness of breath, and nausea during infusion. In the event of clinical signs such as hypotension, syncope, and anaphylaxis, the infusion should be discontinued immediately, and appropriate symptomatic management should be initiated.", "contents": "Small Interfering RNA (siRNA) Therapy -- Enhancing Healthcare Team Outcomes. The healthcare team should administer the abovementioned premedications (corticosteroid, acetaminophen, H1 blocker, and\u00a0H2 blocker) at least 60 minutes before the infusion to prevent an infusion-related reaction. The prescribing and administering clinician should be prepared and equipped for immediate adverse effects such as infusion-related hypersensitivity reactions. The healthcare team should monitor for headaches, back pain, abdominal pain, shortness of breath, and nausea during infusion. In the event of clinical signs such as hypotension, syncope, and anaphylaxis, the infusion should be discontinued immediately, and appropriate symptomatic management should be initiated."}
{"id": "article-143337_46", "title": "Small Interfering RNA (siRNA) Therapy -- Enhancing Healthcare Team Outcomes", "content": "The interprofessional team should educate their patients on the probable adverse effects of siRNA-based therapies and counsel them regarding the appropriate measures. Vitamin A levels\u00a0require routine monitoring by the prescribing healthcare provider for patients receiving patisiran and vutisiran, as the agents are reported to decrease their levels.", "contents": "Small Interfering RNA (siRNA) Therapy -- Enhancing Healthcare Team Outcomes. The interprofessional team should educate their patients on the probable adverse effects of siRNA-based therapies and counsel them regarding the appropriate measures. Vitamin A levels\u00a0require routine monitoring by the prescribing healthcare provider for patients receiving patisiran and vutisiran, as the agents are reported to decrease their levels."}
{"id": "article-143337_47", "title": "Small Interfering RNA (siRNA) Therapy -- Enhancing Healthcare Team Outcomes", "content": "Childbearing females considering treatment with siRNA-based therapies during pregnancy should be evaluated to determine the benefits and risks before starting therapy. Although no studies and data involving pregnant women have been reported, pregnancy risks\u00a0merit discussion. Patisiran reportedly decreases vitamin A levels, which is essential for fetal development. Excess vitamin A levels may also cause adverse developmental consequences. Pregnant patients considering givosiran should be informed about unfavorable fetal developmental outcomes during organogenesis in animal models. Inclisiran should be discontinued during pregnancy.\u00a0Effective communication among the primary healthcare team and specialists treating patients with siRNA-based therapies can reduce complications and enhance quality of life and patient outcomes. [9] [11]", "contents": "Small Interfering RNA (siRNA) Therapy -- Enhancing Healthcare Team Outcomes. Childbearing females considering treatment with siRNA-based therapies during pregnancy should be evaluated to determine the benefits and risks before starting therapy. Although no studies and data involving pregnant women have been reported, pregnancy risks\u00a0merit discussion. Patisiran reportedly decreases vitamin A levels, which is essential for fetal development. Excess vitamin A levels may also cause adverse developmental consequences. Pregnant patients considering givosiran should be informed about unfavorable fetal developmental outcomes during organogenesis in animal models. Inclisiran should be discontinued during pregnancy.\u00a0Effective communication among the primary healthcare team and specialists treating patients with siRNA-based therapies can reduce complications and enhance quality of life and patient outcomes. [9] [11]"}
{"id": "article-143337_48", "title": "Small Interfering RNA (siRNA) Therapy -- Review Questions", "content": "Access free multiple choice questions on this topic. Comment on this article.", "contents": "Small Interfering RNA (siRNA) Therapy -- Review Questions. Access free multiple choice questions on this topic. Comment on this article."}